Westminster, Colorado—Reven Holdings, Inc. (“Reven”) is a privately held clinical stage biotechnology and pharmaceutical company dedicated to the discovery and development of novel treatment platforms for cancer, viral illnesses, and inflammatory disorders. Reven has conducted a randomized, double-blind, placebo-controlled, multi-institutional clinical trial of its lead anti-inflammatory investigational drug product Rejuveinix (RJX) in the treatment of COVID-19. The clinical trial was designed to evaluate the safety and efficacy of RJX in COVID-19 patients.
Reven today announced that it has licensed intellectual property, technology and knowledge pertaining to multiple owned patents supported by a decade of pre-clinical and clinical research in anti-inflammatory effects of bio-similar nutrients to ENS. Peter Lange, the Chief Executive Officer of Reven explained: “We have been eager to partner our research in unique and proprietary blends of vitamins and minerals with a company whose leadership has experience in the development, formulation and sale of successful nutraceutical products.” Brett Hall, Founder and Chief Executive Officer of ENS said, “We have been watching the development of the Reven technology for several years and have been most impressed with the data that has been generated in the areas of anti-inflammatory therapies. “We reached out in hopes to tap into their knowledge base in the formulation and combination techniques used to achieve good clinical outcomes.” Hall further said “It is difficult to achieve consistency and stability over time in vitamin-based products. We were particularly interested in how Reven has been able to overcome the rapid degradation of certain compounds used in their research,”
ENS has plans for developing proprietary nutrient blends for distribution and use in the currently competitive market of “Hydration Therapy” and “IV Nutrition Therapy.” According to Michael Volk, Chief Strategy Officer for Reven, “This multi-billion-dollar market has been around for more than 10 years now, but it started really gaining mainstream attraction during the past few years as an alternative medicine option to those who are either un-insured or under-insured, or who are fed up with dealing with the hurdles involved in the current “standard of care” driven managed medicine environment.” “Reven is excited to see its new product and technology extended into another market.” Reven continues to be laser focused on the highly regulated pharmaceutical market for the completion of the clinical development and future approval of its flagship product RJX which it hopes to gain FDA approval in the future for its use to treat Systemic Inflammatory Response Syndrome and other inflammatory based medical conditions like sepsis, viral and bacterial infections, wound recovery, CLTI and others.
ENS, a Colorado LLC, is a nutraceutical Research and Development company dedicated to creating First-in-class and Best-in-class natural products to help people live their healthiest and most vital life…naturally. At ENS we believe the body possesses the innate ability to heal. Therefore, our primary focus is on creating products that support those natural healing capabilities. By providing the right natural nutrients at the right times in the right amounts, we have observed it is possible to help create an internal physiological environment that supports this powerful, innate healing capability. Our flagship formula, LumiNutra™, focuses on mitigating inflammation and enhancing microcirculation. Through these combined effects we hope to help people reach a state of biological balance and robust health.
About Rejuveinix (RJX)
RJX is an intravenous (IV) formulation of physiologically compatible compounds that is being developed for more effective treatment of patients with sepsis, including COVID-19 patients with viral sepsis and acute respiratory distress syndrome (ARDS). The clinical safety and tolerability of RJX was confirmed in a recently completed double blind, placebo-controlled Phase 1&2 dose-escalation study in healthy volunteers (ClinicalTrials.gov Identifier: NCT03680105).
About Reven Holdings, Inc.
Reven Holdings, Inc., a Delaware corporation, through its Westminster, Colorado based operating company Reven, LLC, is a biopharmaceutical company. Reven’s vision is to make a difference in the world by making its products accessible to everyone suffering the effects of inflammatory, vascular, and metabolic related diseases. Reven is committed to being the premier, research-intensive biopharmaceutical company that advances the health and well-being of people around the world. Its primary product, Rejuveinix (RJX), targets patients suffering from COVID-19, sepsis, vascular and metabolic related diseases as well as specific patient populations suffering Peripheral Arterial Disease (PAD) and other cardiovascular related medical conditions.
Reven’s Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as “may,” “on-track,” “expect,” “anticipate” “hope,” “vision,” “optimism,” “design,” “exciting,” “promising,” “will,” “conviction,” “estimate,” “intend,” “believe” and similar expressions are intended to identify forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about future plans, the progress, timing, clinical development, scope and success of future clinical trials, the reporting of clinical data for the company’s product candidates and the potential use of the company’s product candidates to treat various disease indications. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing market competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates, and unexpected litigation or other disputes. These risks are not exhaustive; the company faces known and unknown risks, including the risk factors described in the company’s periodic SEC filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether as a result of new information regarding future events, or otherwise.
Michael A. Volk, Chief Strategy Officer
Brett Hall, Chief Executive Officer